Home > News > Biophan Names John Lanzafame President of New Nanolution Division
September 16th, 2004
Biophan Names John Lanzafame President of New Nanolution Division
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
Beating the heat a challenge at the nanoscale: Rice University scientists detect thermal boundary that hinders ultracold experiments July 28th, 2016
Ageing can drive progress: Population ageing is likely to boost medicine, nanotechnology and robotics, but increase political risks July 27th, 2016
WSU researchers 'watch' crystal structure change in real time: Breakthrough made possible by new Argonne facility July 27th, 2016
Enhancing molecular imaging with light: New technology platform increases spectroscopic resolution by 4 fold July 27th, 2016
Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016
Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016
GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016
George Clark Named Chief Financial Officer and Associate Laboratory Director for Business Services at Brookhaven Lab February 24th, 2016